GSK plc plans no shift in its dealmaking strategy following the US Federal Trade Commission’s attempt to block Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc, CEO Emma Walmsley told a small group of reporters on 5 June, the first day of the BIO International Convention in Boston. (Also see "Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout" - Pink Sheet, 23 May, 2023.)
Walmsley, who spoke with reporters at the site of one of GSK’s newest acquisitions, Affinivax, Inc. in Cambridge, Mass